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January 2009280 Letters to the Editorease. For example, it was previously reported that the reactivity of
diabetic patients to local heating is impaired,2 and it should be kept
in mind that TcPO2 is measured at 43°C and then automatically
corrected to 37°C.
Second, the standard deviations (SD) of TcPO2 are similar in the
two groups: 11 to 12 mmHg at the chest and 9 mmHg at the foot.
Then the differences between means found between diabetic and
nondiabetic subjects are roughly 0.50 SD at the chest and 0.66 SD at
the foot level. For an equal cost of false-positive and false-negative
tests,mathematically the optimal cutoff point for the discriminationof
the two clinical situations would be half way between the two means
(according to the authors’ results, 55mmHg at the chest and 53mm
Hg at the foot). In a Gaussian distribution, only 20% and 26% of a
population are in the interval mean 0.25 SD andmean 0.33 SD,
respectively.3 Then if TcPO2 should be used as a tool to assess vascular
disease or dysfunction, the sensitivity and specificity of TcPO2 would
both be 60% and 63% at the chest and foot level, respectively. Assum-
ing that the prevalence of diabetes in the population is 10% in
Europe,4 the positive predictive values of a chest TcPO255mmHg
and a foot TcPO253mmHg to detect a diabetic vascular disease or
dysfunction in the population would be12% and 15%, respectively.
Third, as underlined by the authors, TcPO2 is primarily used as
a key point for the diagnosis of critical limb ischemia, amputation
level determination, and wound healing evaluation. Thus, there
are two major issues resulting from this article. The first issue is to
define whether the difference in chest TcPO2 can be found in a
population of patients referred for critical limb ischemia. The
second issue is that in diabetes, a number of factors, including
neuropathy, may induce foot lesions independently from the pres-
ence of arterial disease. Thus, contrary to the chest TcPO2 and due
to a higher prevalence of foot lesions unrelated to vascular disease,
the foot TcPO2 in diabetic patients with suspected foot ulcer or
critical limb ischemia could on the average be higher than in
nondiabetic subjects.
Thereby, although the difference between the two groups is
significant, we think that the discriminative power of the sole
resting value for TcPO2 is insufficient to be useful in clinical
practice as an additional diagnostic tool to assess subclinical periph-
eral vascular disease of diabetic origin.
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Reply
We thank Jaquinandi et al for commenting on our research
article “Reference value of transcutaneous oxygen measurement in
diabetic patients compared to non-diabetic patients.”1We agree that one should always be aware that confounding
factors might have modified the outcome. To prevent bias from
confounding, we matched the study groups for age and sex.
Furthermore, we controlled for several possible confounding
variables using multivariate analysis. Although not recorded,
skin thickness and use of vasoactive drugs may influence TcPO2
measurements but are unlikely to have been significantly differ-
ent in both groups. In contrast to what Jaquinandi et al wrote,
we concluded that subclinical microvascular impairment was
responsible for the observed differences in TcPO2 outcome, and
not vascular disease. We therefore acknowledge the impaired
reactivity of diabetic patients to local heating, which could be a
result from vascular dysfunction in their skin microcirculation.
Second, we did not propose TcPO2 measurement as a distinc-
tive modality to detect diabetic vascular disease or dysfunction in
the general population, but as an additional diagnostic tool that
may be helpful to detect occult microvascular dysfunction in
diabetic patients at risk for peripheral vascular disease. It has been
shown that TcPO2 measurement can be a useful modality to
prevent peripheral vascular disease in diabetic patients because it
allows detection of early changes in skin oxygenation before the
development of clinically overt microangiopathy.2
Although the theoretic values for sensitivity and specificity
may have been well calculated by Jaquinandi et al to compare
the discriminative capacity of TcPO2 measurement between
diabetic and nondiabetic patients, this was not our research
objective. Moreover, we believe that calculating a positive pre-
dictive value (PPV) to detect a diabetic vascular disease or
dysfunction in the general population from our results, at best,
can be considered overstretched. We do not think it is justified
to calculate sensitivity, specificity, or PPV for TcPO2 measure-
ment as a predictor for microvascular dysfunction in diabetic
patients because we cannot provide a rationale to pick a scien-
tifically based cutoff point.
Others, however, have previously investigated the use of
TcPO2 measurement as a predictor for outcome of diabetic foot
ulcers.3 They found that when using 25 mm Hg as a cutoff
point, TcPO2 measurement is a better predictor for ulcer healing
in diabetic patients (PPV, 79%) compared with toe blood pres-
sure (PPV, 67%). Instead of using TcPO2 measurement as a
discriminative screenings modality for diabetic vascular disease
or dysfunction, we would advocate to record consecutive results
on a per-patient basis to detect microvascular impairment and to
evaluate possible progression to peripheral vascular disease.
Further, Jaquinandi et al questioned whether the observed
difference in TcPO2 measurement at chest level between dia-
betic and nondiabetic patients could be found in a population of
patients referred for critical limb ischemia. Williams et al4
recently reported mean TcPO2 values (foot/chest) of 63/71
mm Hg for nondiabetic patients without vascular disease, and
63/60 mm Hg for nondiabetic patients with vascular disease.
Mean TcPO2 values for diabetic patients without or with vascu-
lar disease were 56/57 mm Hg and 57/53 mm Hg, respec-
tively. Although we do not have an explanation for the lower
TcPO2 values at the chest level of diabetic patients with or
without vascular disease, this study is in accordance with our
reported results.
We acknowledge their final comment that TcPO2 values at the
foot in diabetic patients with suspected foot ulcer or critical limb
ischemia could on the average be higher than in nondiabetic
patients. We have, however, not been able to investigate this
because all our participants were free of signs of both peripheral
disease and neuropathy.
According to our original research question, we believe that
consistent reference values for TcPO2 are crucial in order to evalu-
ate diabetic patients with a foot at risk, and we would like to
maintain our conclusion that the TcPO2 measurement may be a
useful additional diagnostic modality to detect subclinical micro-
vascular impairment in diabetic patients in order to monitor and
even prevent progression to peripheral vascular disease.
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Regarding “Functional outcome after
thoracoabdominal aneurysm repair”
The authors are commended for their aim to look beyond
simple mortality statistics and assess long-term outcomes after
thoracoabdominal intervention.1 The assumption that such a large
intervention may impact long-term quality of life is intuitive, and
investigating the details of this impact will inform future practice.
We are, however, concerned about the conclusions being drawn
from the current study due to the nature of the respondents, and
the generalizability of this data to the preoperative thoracoabdomi-
nal population.
On the first point, it should be emphasized that in reviewing
the patients eligible for inclusion, the authors found that only
47% of their cohort (204 of 435) survived to be included in this
analysis, on average five years. Further to that, the response rate
of the survey was 67%, which diminished the number of patients
from whom this information is gathered to 134 people, or
30.8% of the original population. A conclusion stating that
“Permanent loss of functional capacity . . . occurs rarely in sur-
vivors of thoracobdominal aortic aneurysm (TAAA) repair” may
have been carefully worded, but is misleading in that the
majority of patients who underwent the procedure did notsurvive to contribute to the data presented, and those who did
may have, by definition, a higher functional capacity. The
interpretation is further challenged by the lack of baseline data
in the study population, which makes it difficult to ascertain if
the performance after five years of convalescence is actually a return
to the age-appropriate norm, or a deterioration in what was likely an
exceptional group of patients.
This leads to the second point, in which the generalizability of
these outcomes to the population of all TAAA is challenging
because of the large cohort who did not survive or were not able to
complete the questionnaire. If this small population of patients
who do relatively well could be predicted in advance of surgery,
then this quality of life data would be applicable. However, we feel
the selection bias present in the sample challenges the utility of the
data gathered. We believe the only way to truly determine the
effect that any form of intervention for thoracoabdominal aneu-
rysm has on the patients in whom it is performed is a protocolized
and prospective longitudinal study for all patients presenting with
thoracoabdominal disease.
Tara M. Mastracci, MD
Roy K. Greenberg, MD
The Cleveland Clinic Foundation
Cleveland, Ohio
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Drs Greenberg and Mastracci raise concerns about the gener-
alizability of our results given the stated mortality rate in our study,
the response rate obtained from our survey, and our lack of
available baseline quality of life (QOL) score. A suggestion is made
that a protocolized, prospective, longitudinal study would help us
more accurately determine the effect of an intervention for thora-
coabdominal aneurysm repair (TAA).
On the first point, our published 5-year mortality rate of 47%
is in line with other published large series for thoracoabdominal
aneurysm repair.1 Given that this is a long-term functional out-
come study in survivors of TAA repair, even a prospective study
would not allow us to improve on our ability to get more complete
data at the 5-year time point.
On the second point, surely a 100% response rate would be
desired. There is no definitive acceptable mail response rate (ie, free
from response bias); it can range from 30-70% depending on the
methodology being used (ie, established panel or randommailing,
etc). QualityMetric (Lincoln, RI) has typically had a 60-70% mail
response rate in its SF-36/SF-36v2 norming studies (personal
communication). Our response rate of 67% is comparable to this,
thus our cohort data accurately reflects the long term functional
outcomes of the group as a whole.
On the third point, we certainly agree that having a baseline
QOL score would be the optimal methodology; absent this the
QualityMetric norm-population, although controlled for age, is
obviously irrelevant to a population of TAA patients. An effort
was made to find a comparable group of patients, from both a
co-morbidity and age stand-point, to use as a control. We
believe that the comparison to the cardiovascular disease cohort
used provides the most accurate surrogate to baseline QOL
scores.
A recently published report by Zierer, et al2 on 25 survivors
of TAA, using the same SF36 tool at an average of 3 years, found
results remarkably consistent with our own. Outcome studies
after open TAA repair that paint a pessimistic picture3 after TAA
